Skip to content
Screener

Syndax Pharmaceuticals SNDX Business Segments — Other General And Administrative Expense

Similar metrics at other companies

Jaguar Uranium logo
JAGUOntario — Other General And Administrative Expense
$18K
LifeMD, Inc. logo
LFMDTelehealth — Other General And Administrative Expense
$8.47M+17.8%
Consolidated Water Company logo
CWCOBulk — Other General And Administrative Expense
$119.6K-34.7%
Consolidated Water Company logo
CWCOCorporate — Other General And Administrative Expense
$939.85K+29.2%
Consolidated Water Company logo
CWCOServices — Other General And Administrative Expense
$371.57K+12.1%
ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Other General And Administrative Expense
$2.31M+7.4%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.82B+69.0%
Enterprise value$2.04B+57.0%
P/S8.4×-5.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
March 31, 2026Three Months Ended March 31, 2026Three Months Ended March 31, 2025
General and administrative expenses
Commercial related expenses7,72110,825
Personnel cost and other expenses16,70119,082
Other SG&A expenses5,1404,412
Stock-based compensation12,05310,380
Royalty interest expense11,8468,049
Interest expense (income), net(3,561)(7,181)
Other expense, net186221

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's business segments — other general and administrative expense?
Syndax Pharmaceuticals (SNDX) reported business segments — other general and administrative expense of $5.14M in Q1 2026.
How has Syndax Pharmaceuticals's business segments — other general and administrative expense changed year-over-year?
Syndax Pharmaceuticals's business segments — other general and administrative expense increased by 16.5% year-over-year, from $4.41M to $5.14M.
What is the long-term trend for Syndax Pharmaceuticals's business segments — other general and administrative expense?
Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — other general and administrative expense has grown at a 33.3% compound annual growth rate (CAGR), from $9.84M to $23.31M.
What does business segments — other general and administrative expense mean?
This includes miscellaneous administrative costs such as legal, consulting, and facility expenses allocated to the cancer therapeutics segment. It represents the non-personnel overhead required to maintain the business unit's infrastructure. Consistent monitoring helps identify trends in corporate overhead and operational efficiency.

Ask your AI about Syndax Pharmaceuticals's business segments — other general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude